Literature DB >> 30863839

In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis.

Wesley D Kufel1,2,3, Ambika P Eranki2, Kristopher M Paolino2, Andrea Call4, Christopher D Miller2,3, Bryan T Mogle3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30863839     DOI： 10.1093/jac/dkz103

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Erin K McCreary; Rachel V Marini; Ellen G Kline; Chelsea E Jones; Binghua Hao; Liang Chen; Barry N Kreiswirth; Yohei Doi; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

Review 2.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 3.  Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review.

Authors:  Julie Gorham; Fabio Silvio Taccone; Maya Hites
Journal:  Antibiotics (Basel)       Date:  2022-04-20

Review 4.  New evidence in severe pneumonia: meropenem-vaborbactam.

Authors:  M Forteza Guillot; M Martín Cerezuela; P Ramírez
Journal:  Rev Esp Quimioter       Date:  2022-04-22       Impact factor: 2.515

5.  Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.

Authors:  Eric Wenzler; David Butler; Xing Tan; Takayuki Katsube; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2021-11-18       Impact factor: 5.577

Review 6.  Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors.

Authors:  Giacomo Luci; Francesca Mattioli; Marco Falcone; Antonello Di Paolo
Journal:  Antibiotics (Basel)       Date:  2021-06-24

Review 7.  Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics.

Authors:  Milo Gatti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2021-06-14       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.